My research and clinical interests revolve around the development of targeted therapies for KRAS-mutant NSCLC as well as novel strategies to overcome resistance to targeted therapies for EGFR-mutant and MET-altered NSCLC.
My three main research themes are: 1.) Novel pre-clinical target validation and drug development (TWIST1 in oncogene-driven NSCLC and TKI resistance; targeting metabolism in oncogene-driven lung cancer); 2.) Elucidating mechanisms of resistance for targeted inhibitors to develop rationale therapeutic combinations that can be tested in the clinic; 3.) Development of targeted therapy approaches for the treatment of brain metastases.

The first line of research focuses on the role of the EMT transcription factor TWIST1 in oncogene-driven NSCLC and therapeutic resistance. The second line focuses on mechanisms of resistance to targeted agents in phase 1 and 2 trials. The third line explores lung cancer brain metastases, targeting the HGF-MET-TWIST1 pathway and downstream metabolic pathways, alone or with immunotherapy. We also conduct translational studies (ctDNA, radiomics) to bring findings to the clinic.